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Acetyicholine
endothelium-derived relaxing/contracting factors 575
Acid, basolateral transport of H/HCO3 1077
Acid-base
balance, bone 9
balance, dialysate and substitution fluid buffer 711
hypotonic stress, KHCO3 release in MDCK cells 891
mouse CCD cell line 1169
Acidification
precalyceal tubular ectasia (abst) 360
urine anion gap (abst) 1066
Acidosis, bone in acid-base balance 9
Actin
mesangial cells, alpha smooth muscle (abst) 1302
Acute cystitis, renal involvement 541
Acute interstitial nephritis
clinical outcome (abst) 355
Acute pyelonephritis
clinical study (abst) 1062
renal involvement 541
Acute renal failure
clinical outcome of transplants (abst). . . 211, 211, 211, 212
continuous HF (abst) 1306
differential gene expression, recovery from ischemia. 1157
endothelium derived factors 575
etiology (abst) 1327
hantavirus infection (abst) 1318
iron metabolism and Al 799
lipopolysaceharide-mediated renal injury 618
outcome (abst) 1331
oxidants, elastase, LPS injury 618
vascular reactivity in ischemic 1087
Acute tubular necrosis
role of PFOB enhanced sonography 733
Adenine arabinoside, hepatitis B 301
Adenine nucleotide pools, myoglobin Ill
Adenine nucleotides, inflammation (abst) 1051
Adenosine
graded oxygen tension effects on mTAL 836
mediates TGF 32:S-l29
receptors, JG cells, renin release 32:S-16
ADPKD
brain aneurysm (abst) 1322
c-myc gene in PKD 665
genetic markers (abst) 1307
tubulocystic epithelium 450
Adriamycin nephrosis, sodium depletion (abst) 1053
Afferent arterioles
communication between macula densa cells 32:S-79




natriuresis, CNS induced (abst) 1325
outcome of dialysis (abst) 1333
patient, dialysis-related amyloidosis 1012
Agonists
dopaexamine (abst) 1334
endothelium derived factors 575
Albumin
beta blockade (abst) 1307
glycosylated, diabetes (abst) 1300
microalbuminuric IDDM patients (abst) 1053
receptor mediated endocytosis (abst) 1314
Albumin-lasix therapy, nephrosis (abst) 205
Aldosterone in MCNS (abst) 205
Alkalosis, mannitol (abst) 1057
Allele, DQw7, IgAN susceptibility 961
Allergy, childhood nephrotic syndrome (abst) 1060
Allograft
expression of ICAM-l (abst) 1309
function, atriopeptin 3 164
survival (abst) 213
survival of cadaveric (abst) 1332
thromboembotic complications (abst) 1308
vascular complement, adhesion, rejection (abst) 1302
Allotypes in IgAN in Blacks 1219
Alpha1-microglobulin, uninephrectomy (abst) 1323
Aluminum
calcium influx, efflux from bone 602
cellular uptake and iron 799
containing antiacids, intoxication (abst) 1329
dietary influences on absorption/retention 598
toxicity (abst) 1310
Amikacin removal in CAVH (abst) 1068
Amino acids
diet, children with CRF (abst) 1317
free, ribosome content in HD 984
homeobox genes in PT 1027
Aminoguanidine, diabetes (abst) 1306
Aminopenicillins, gyrase inhibitors, CsA (abst) 1317
Aminopeptidase A (abst) 1056
Amphiuma, tubuloglomerular feedback, chloride.... 32:S-69
Amyloidosis
aspects of f32m (abst) 356
deposition of /32m in bone in CRF 990
diagnosis (abst) 186
dialysis related (abst) 1315
dialysis-related, patient age, membranes 1012
Anaplerosis, pyruvate carboxylase in nephron 1163
Anatomy, renal interstitium 370
Anemia
autoimmune hemolytic (abst) 213
brain function with rHuEPO therapy 155
cardiopulmonary function, EPO (abst) 196
low iron diet, hemodynamics 647
polyamines in ESRD 725
rHuEPO (abst) 203
Aneurysm, ureteral obstruction (abst) 1068
Angioplasty




morphology of juxtaglomerulus 32:S-9
renin system, CsA 32:S-28
1366
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Angiotensin II
angiogenic action, growth 32:S-38
luminal, Na transport in PT 32:S-34
mesangial cell function, chloride ions 32:S-66
production, JG cells 32:S-20
production, renin like activity in PT 938
Angiotensin converting enzyme inhibition
angiogenic action of Ang II 32:S-38
changes in PRA, ANF and NE (abst) 1312
renin inhibition (abst) 1305
renin, RVH (abst) 1309
size-selectivity in IgAN 1268
urate clearance (abst) 195
Angiotensinase A, image analysis (abst) 1313
Angiotensinogen production, renin-like activity in PT... 938
Anion, modulation of K secretion 1207
Anti-GBM glomerulonephritis
interleukin 1 production 103
Antiacids, severe Al intoxication (abst) 1329
Antibiotics
gentamicin nephrotoxicity 639
urinary tract (abst) 1061
urinary tract infection (abst) 1062
Antibodies
anti-DNA, epethelial adhesion (abst) 1054
anti-GBM, Wegener's, ANCA, GPS (abst) 1316
anti-phospholipid, lupus nephritis 1226
circulating anti-entactin, GN 996
different vasculides (abst) 1301
hepatitis C (abst) 192
immune complex-derived anti-DNA, lupus 746
in SLE-like syndromes (abst) 1052
nephritogenic monoclonal (abst) 1056
positive C-ANCA in RPGN (abst) 1300
pyruvate carboxylase along the nephron 1163
Antigens
children, HBsAg in MGN (abst) 207
glomerular visceral epithelium 71
immune system 518
in Wegener's granulomatosis (abst) 1053
induction of MHC-class II (abst) 1302
nephritogenic tubulointerstitial 501
organ sharing using HLA typing 557
Antithymocyte serum induced lesions, TGF 32:S-120
Apolipoproteins
hyperlipidemia of NS 31:S-8
metabolism 31:S-3
Apoproteins, lipid abnormalities in renal disease 170
Arachidonic acid, metabolism 438
Arachinodyl COA synthetase (abst) 356
Arginine vasopressin
clearance, cirrhosis (abst) 190
extracellular Na, PCT 591
receptors in diabetes 693
thirst, CRF 295
Arterial calcification, Mg, hemodialysis (abst) 201
Arterioles
branching, confluence pattern 32:S-2
efferent, TGF 32:S-72
tubuloglomerular feedback signals 32:S-46
vasoactive substances, afferent 32:S-87
Asymptomatic bacteriuria, renal involvement 541
Atherogenic risk, proteinuria (abst) 1311
Atheromatous embolization, hypocomplementemia 811
Atherosclerosis
lipid disorders posl;-transplant 31:S-24
mechanisms, GS 31:S-29
renal artery disease, Doppler scan 1233
ATPase, hypertension (abst) 357, 357
Atrial natriuretic factor
allograft function, atriopeptin 3 164
blunted release post-exercise (abst) 205
Atrial natriuretic peptides
central system, hypertension 33
hypertension (abst) 205
nephrectomy (abst) 1058
Atriopeptin 3, renal allograft function 164
Autoantibodies, murine monoclonal lupus (abst) 187
Autoregulation
blood flow dynamics 32:99
microvascular 32:S-90
oscillations of TGF 32:S-95
vascular reactivity in ischemia 1087
volume expansion, TGF 32:S 149
Autovaccination in UT! patients (abst) 1314
Basolateral membrane
organic cation/anion transport (abst) 1300
Berger's disease
allotypes for IgAN in Blacks 1219
Beta2-microglobulin
amyloidosis (abst) 356
changes in UT! (ahst) 1067
deposition in bone in CRF 990
dialysis (abst) 192
dialysis related amyloidosis, patient age 1012
kinetics, ESRF 909
Bicarbonate, modulation of K secretion by anions 1207
Binding sites for VIP 266
Biopsy
allotypes of IgAN in Blacks 1219
analysis of 2514 cases (abst) 215
anti-entactin antibodies in GN 996
chronic carbon disulfide intoxication (abst) 207
deposition of CLI, NEO-C9 and S-protein (abst) . . . . 1328
diagnosis of amyloidosis (abst) 186






allotypes and clinical course of IgA.N 1219
Blood
access for HD (abst) 196
changes in CRF (abst) 361
cholesterol, nephrolithiasis 1250
control of pH, base secretion (abst) i3l5
diagnosis of hematuria in children (abst) 207
dialysis hypotension 233
mononuclear cells, IgAN, proto-oncogenes 946
procoagulation, fibrinolytic activity in GN i214
transfusions, CsA 328
Blood flow
afferent arteriole, MD generated signals 32:S-75
angiogenic action of Ang II 32:S-38
basolateral transport of H/FICO3 1077
dynamics in autoregulation 32:S-99
graded oxyten tension, adenosine release in mTAL. . . 836
1368 Subject Index: Vol. 39
insulin-like growth factor 1 333
peritoneal dialysis, ultrafiltration 608
vascular reactivity in ischemia 1087
volume expansion, TGF 32:S-149
Blood pressure
central ANF system in hypertension 33
dynamics in TGF 32:S-95
hyperreactivity of TOF in SHR 32:S-143
one-kidney, one clip hypertension, TGF 32:S-116
role of K 771
tubuloglomerular feedback mechanism, SHR 1185
Bone
acid-base balance 9
alterations in transplantation (abst) 197
aluminum alters Ca influx/efflux 602
amyloidosis, patient age, dialysis membrane 1012
appendicular metabolism (abst) 197
calcium influx/efflux, Al 602
density in ESRD children (abst) 200
deposition of /32m in CRF 990
diagnosis of osteodystrophy (abst) 197
diet, vitamin D, calcium stone formers 1194
dietary K, urinary Ca excretion 973
human cytomegalovirus DNA (abst) 1310
lesions (abst) 361
mass, CAPD (abst) 199
metabolism markers (abst) 1316
mineral content, CRF (abst) 210
mineral density in normal children (abst) 1059
mineral density post-transplantation (abst) 1059
morphology in HD (abst) 1329
osteoblast mitogenesis in uremia 942
osteodystrophy indices (abst) 199
phosphate (abst) 361
transplantation, density in children (abst) 200
turnover in uremia (abst) 1308
Bradykinin
endothelium-derived relaxing/contracting factors 575
Brain
aneurysm and ADPKD (abst) 1322
correction of chronic hyponatremia 1275
parathyroid hormone levels (abst) 193
Bright's disease, Pierre Rayer 787
Brush border membrane
binding sites for VIP 266
protein from PT (abst) 1300
Buffers
intracellular H, pH 282
kinetics in HDF 711
C3, C4, CH5O, hypocomplementemia 811
CAPD
beclobrate, hyperlipidemia (abst) 1309
bone mass (abst) 199
calcium kinetics (abst) 1308
diabetes (abst) 1301
dietary protein (abst) 1331
epidemiology of peritonitis (abst) 1330
fungal peritonitis (abst) 1064
future trends (abst) 355
gram negative peritonitis (abst) 1063
interleukin lbeta release (abst) 1052
nifedipine, ultrafiltration (abst) 191





permeability for proteins, TNFa (abst) 1304
polyamines in anemia of ESRD 725
three daily exchanges (abst) 1320
urea kinetics 700
verapamil, ultrafiltration (abst) 191
vitamin D metabolism, peritoneal macrophages 1005
CA VII
outcome (abst) 1331
removal of Amikacin (abst) 1068
CV-6504(HC1), PAN-induced nephrosis treatment 920
Cadmium intoxication (abst) 1060
Calcification
bone and Al 602
Calcitriol
bone mineral density in ESRD (abst) 1329
Calcium
clinical characteristics of hypercalcemia (abst) 1066
effect of sodium in PCT 591
extracellular Na effects on cytosolic 591
fluorescence measurements 32:S-56
hypertension (abst) 206
influx/efflux in bone, Al 602
intraplatelet concentrations, uremia (abst) 210
kinetics in CAPD (abst) 1308
kinetics post-parathyroidectomy (abst) 199
levels, Na intake, hypertension (abst) 187
stone formers, diet and vitamin D 1194
transients of intracellular (abst) 1318
urinary excretion, K 973
Calcium carbonate therapy (abst) 198
Calcium oxalate
glycolate in urine 765
nephrolithiasis, defective oxalate transport 1284
Calculi
in urine of transplant patients (abst) 213
precalyceal tubular ectasia (abst) 360
uric acid, dissolve (abst) 1061
urolithiasis (abst) 194
Capillaries
branching and confluence 32:S-2
role of PT reabsorption in GFR 32:S-l33
Captopril
hypertension (abst) 1060
post-transplant erythrocytosis (abst) 1321
renal artery disease (abst) 1301
Carbon disulfide intoxication (abst) 207, 216
Carcinoma, incidentally detected cell (abst) 1061
Cardiopulmonary resuscitation, dialysis (abst) 196
Cardiovascular
atherosclerosis, lipid disorders post-transplant. . . . 31:S-24
Carpal tunnel syndrome
membrane, patient age, amyloidosis 1012
Catheters
dual lumen (abst) 1330
monocyte stimulation (abst) 1322
non-surgical implantation of Tenckoff (abst) 191
permanent peritoneal dialysis (abst) 191
permeability to HBsAg (abst) 1320
urine cultures (abst) 195
Cells
activated (IL-2R+) in crescentic GN 793
anatomy of interstitium 370
Subject Index: Vol. 39 1369
angiotensin Ii production, JG 32:S-20
arachidonic acid metabolism 438
biology of ischemic injury 476
cable analysis, hormones and heavy metals (abst) . . . 1312
communication of tubuloglomerular feedback
system 32:S-46
contractile proteins in mesangial cells 1118
cortical collecting duct cell line 1169
cyclosporine metabolites in mesangial 1256
desferrioxamine, TNF release in mesangial 822
drugs and tubulointerstitial 531
endothelium derived factors 575
extracellular Na in PCT 591
fibrosis 550
glycine in mTAL injury 653
homeobox genes in PT 1027
homeostasis, H/HCO1 1077
hypertrophy and hyperplasia 401
incidentally detected carcinoma (abst) 1061
immune system in interstitium 518
intracellular H, pH 282
juxtaglomerular, renin 32:S-13
macula densa function 32:S-40
mesangial contraction, PAF 624
morphology of juxtaglomerular 32:S-9
organ sharing using HLA typing 557
preferential binding of LDL to mesangial 858
procoagulant, fibrinolytic activity in GN 1214
proto-oncogene expression, IgAN 946
puromycin, metanephric differentiation 1141
stress induced release of KHCO1 in MDCK 891
transport pathways in MD 32:S-60
tubular basement membranes 382
tubulointerstitial 394
uptake of Al, iron 799
Central ANF system, hypertension 33
Chemotherapy
genitourinary tuberculosis (abst) 209
stage IIIB myeloma (abst) 1324
Children
adult kidney transplantation to 129
compliance with transplantation (abst) 354
cortisone, growth hormone release 1136
diagnostic tools for UTI (abst) 1062
estimation of kidney size from body size (abst) 1069
hematuria, metabolic disturbance 707
infant pupura nephropathy (abst) 1315
nephrotic syndrome in S. Africa (abst) 359
outcome of HUS (abst) 358
transplantation (abst) 212
vesicoureteral reflux (abst) 1063
Chloride
in MD and CTAL cells 32:S-52
ions, mesangial cell function 32:S-66
tubuloglomerular feedback in JG 32:S-69
Chlorothiazide
treatment (abst) 200
Chiorpropamide, water and urea transport 79
Chronic hyponatremia, neurology 1275
Chronic renal failure
amino/keto acids, diet, children (abst) 1317
arachinodyl COA synthetase (abst) 356
bone mineral content (abst) 210
brain function with rHuEPO therapy 155
calcium flux in bone, Al 602
cell mediated immunity (abst) 1064
demographics (abst) 193
deposition of f32m in bone 990
dietary prostaglandin precursors, progression 31:S-57
diet and PTH (abst) 1326
diet, lipid abnormalities 31:5-70
elevated IL-6 954
endothelium derived factors 575
fatty acid profiles (abst) 356
insulin sensitivity, K handling in uremia 39
lipids (abst) 185, 187
lithium clearance (abst) 1328
low density lipoproteins (abst) 188
melatonin status (abst) 356
microvascular changes (abst) 361
nebulized salbutamol (abst) 1067
progression (abst) 188
regulation of PTH 874
renovascular hypertension 966
ribosome, free amino acid content in muscle 984
salbutamol (abst) 1058
stone disease, bowel resection (abst) 1328
thirst and vasopressin 295
tuberculosis (abst) 209
tuberous sclerosis '(abst) 215




Cimetidine, glomerular filtration (abst) 1053
Cirrhosis, arginine vasopressin, clearance (abst) 190
Clearance
beta2-microglobulin kinetics 909
measurement with 99mTcMAG3, 131J-OIH (abst) . . . .
plasma prorenin post-obstruction 901
size-selectivity in IgAN, ACEI 1268
urate, ACEI (abst) 195
Clindamycin, peritonitis treatment (abst) [301
Clinical outcome, urea kinetic indices in CAPD 700
Clusterin, Heymann nephritis 247
Collagen, glycation end products (abst) 1302
Collecting ducts
insulin-like growth factor I 27
terminal, Na handling by deep nephrons 850
Colloid and cellular vacuolation 672
Complement
biopsy, CLI deposits, NEO-C9 and S-protein (abst).. 1328
system, hypocomplementemia 811
Computer management of transplantation (abst) 354
Congestive heart failure
ibopamine (abst) 1054
therapy, ACE! (abst) 1300
Contractile proteins, biochemistry 1118
Converting enzyme inhibitors
one-kidney, one-clip hypertension, TGF 32:S-l16
Coronary heart disease
treatment during HD (abst) 1304
Corrosion casts, arterioles 32:S-2
Cortex
cyclosporine 631
pyruvate carboxylase along the nephron 1163
Cortical collecting ducts
characterization of cell line 1169
immunohistochemistry, fibroblasts (abst) 1311
modulation of K secretion 1207
1370 Subject Index: Vol. 39
prostaglandin E2 (abst) 1303
Cortical thick ascending limb
action of furosemide 32:S-56
chloride concentration 32:S-52
transport pathways in MD 32:S-60
Cortisone, growth hormone release 1136
Countertransport
red cell Na/Li, diabetes 135
Creatinine
marker of GFR 1053
progression of CRF (abst) 188
Crescentic glomerulonephritis
activated (IL-2R+) intraglomerular mononuclear
cells 793
Cuprophane, interleukin-2 expression 1020
Cyclic AMP
extracellular Na, PCT 591
phosphorylation of proteins (abst) 357
sodium effect in PCT 591
Cyclophosphamide, lupus nephritis (abst) 1321
Cyclosporin A
convert to Aza (abst) 215
increases GFR (abst) 1312
steroids in iupus nephropathy (abst) 1328
succinate dehydrogenase (abst) 1313
therapy (abst) 204, 206, 206, 211




effect in PAN-induced nephrosis (abst) 1060
endothelium derived factors 575
lipid abnormalities (abst) 1332
metabolites, effect on mesangial cells 1256
nephrotoxicity (abst) 353
pharmacokinetics (abst) 1317
pharmacokinetics of prednisone in transplantation... 1034
procollagen al mRNA levels 631
renin-angiotenin system 32:S-28
Cysts
c-myc induces PKD 665
cytokines in PKD 718
deposition of f32m in bone in CRF 990
epidermal growth factor 57
presymptom diagnosis of PKD (abst) 187
role of PFOB enhanced sonography 733
tubulocystic epithelium 450
Cytokines
elevated IL-6 in CRF 954
fibrosis 550
first dose OKT3 reaction 141
interleukin-8 in mesangium 1241
polycystic kidneys 718
Cytomegalovirus
detection in IgAN biopsy (abst) 1311
infections, gancyclovir (abst) 1319
in PT cells (abst) 1055
DNA
frequency of DQw7 allele in IgAN 961
homeobox genes in PT 1027
polymerase chain reaction techniques 32:S-23
DQw7 allele in IgAN 961
Deep nephrons, Na handling 850
Deep-etch, quick-freeze methods, GBM 659
Deferoxamine, toxicity in HF (abst) 1316
Desferrioxamine, TNF release 822




cardiovascular events (abst) 1307
continuous CAPD (abst) 1301
epidemiology, HD (abst) 1307
hyperlipidemia and progression 31:S-41
lipid abnormalities (abst) 1307
micral-test (abst) 1310
post-transplant (abst) 1065
protein modulates GFR (abst) 190
regulation in inner medulla (abst) 1303
type 2, transplantation in older (abst) 193
Diabetes insipidus
platelet vasopressin receptors 693
Diabetes mellitus
extracellular volume, hyperfiltration 1177
hypertrophy, TGF 32:S-107




red cell Na/Li countertransport 135
Dialysate
beta2-microglobulin kinetics 909
blood flow during UF 608
diet and Al toxicity 598
potassium excretion (abst) 192
rocaltrol (l,25(OH)2-cholecalciferol) (abst) 1059
substitution fluid buffer 711
three daily exchanges in CAPD (abst) 1320
Dialysis
anemia and EPO (abst) 1306
/32-microglobulin (abst) 192
blood flow during UF 608, 608
body composition, modality (abst) 1331
brain function with rHuEPO therapy 155
calcium flux in bone, Al 602
chronic, CPR (abst) 196
comparisons (abst) 201
demographics of CRF (abst) 193
dietary protein (abst) 1331
erosive spondyloarthropathy (abst) 1323
erythropoietin (abst) 1319
etiology of ARF (abst) 1327
future trends (abst) 355
glycolate detects hyperoxaluria 149
hypotension 233
index, 4 methods (abst) 189
interleukin 2 (abst) 216
left arterial volume (abst) 203
membrane permeability to HBsAG (abst) 1320
osteoblast mitogenesis in uremia 942
outcome in elderly (abst) 1333
paired filtration (abst) 189
parathyroidectomy (abst) 197
permanent peritoneal catheters (abst) 191
related amyloidosis, membranes and age 1012
ribosome and free amino acid content in muscle 984
urea kinetic indices and outcome 700
Dialysis index
urea kinetic indices and CAPD 700
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Dialysis, peritoneal
ultrafiltration, blood flow 608
Diet
blood pressure, TGF in salt loaded SHR 1185
fatty acids in FGS 930
fatty acids in obese Zucker rats 1126
hypercalciuric Ca stone former 1194
hyperlipidemia and progression 31:S-41
hypophosphatemia (abst) 1057
influence on Al absorption, retention 598
low iron, hemodynamics 647
manipulations, CRF, lipids 31:S-70
muscle protein synthesis 831
pharmacological treatment, lipid disorders 31:S-65
potassium, urinary Ca excretion 973
prostaglandin precursors, progression 31 :S-57
role of K in hypertension 771
treatment for progression of injury 31:S-49
Diuretics 336
sulfhydryl reagents, renin secretion 867
Donor
adult kidney transplant to child 129
age affects transplant (abst) 215
crossmatch (abst) 204, 212
healthy, glomerular and tubular function (abst) 1058
living, clinical (abst) 1064
outcome (abst) 1334
specific transfusion (abst) 212, 214
unrelated living (abst) 354
Dopamine, receptor blockade, hypervolemia 253
Dopexamine, agonist (abst) 1334
Drugs
cyclosporine, mRNA levels in cortex 631
nephrotoxicity 531
pharmacological, dietary treatment,lipid disorders. 31:S-65
Duplex scanning, renal artery disease 1233
Duplex sonography, allograft rejection (abst) 1305
Dyscrasia, POEMS syndrome (abst) 1333
Edema
bilateral papillar (abst) 1320
diuretics 336
hyperlipidemia in NS 31:S-8
idiopathic, metabolic alkalosis (abst) 1066
lipids and progression 31:S-35
Efferent arteriole, role in TGF 32:S-72
Eicosanoids
electric properties of MDCK (abst) 1314
fatty acids in FGS 930
hyperfiltration and progression of RF (abst) 1051
Elastase
lipopolysaccharide-mediated renal injury 618
Electrolytes
balance, chronic salt loading, TGF 32:S-137
serum, transplantation (abst) 1065
Emphysematous pyelonephritis (abst) 1063
Enalapril, in uninephrectomized SHR 1112
End-stage renal disease
bone density in children (abst) 200
calcitriol, BMD (abst) 1329
children (abst) 361
dialysis modality (abst) 1331
fibrosis 550
hepatitis B vaccine (abst) 209
liver biopsy, hyperoxaluria (abst) 1321
liver disease, HBsAg carriers (abst) 1061
phagocytosis 320
polyamines in anemia of 725
tubulointerstitium in diabetes 464
vasopressor effect of rHuEPO 259
vitamin D metabolism, peritoneal macrophages 1005
End-stage renal failure
beta2-microglobulin kinetics 909




systems, ACE! (abst) 1312
Endothelin
cardiomyocytes (abst) 1308
effects on TGF 32:S-l23
mesangial cell contraction, PAF 624
Endothelin- 1
excretion in renal disease 307
Endothelium
activation of hypertensive (abst) 1326
derived relaxing/contracting factors 575
Entotoxin, PG mechanism (abst) 1326
Enzymes
arachidonic acid metabolism 438
glycolytic activity in urine (abst) 194
hypertension, 11BOH beta 357
inhibition of ACE, IgAN 1268
ornithine decarboxylase, lupus nephritis 882
plasma lipoprotein metabolism 3 l:S-3
pyruvate carboxylase 1163
Epithelial cells
channel mediated, base secretion (abst) 1315
eicosanoids, electrical properties of MDCK (abst) . . . 1315
hypertonic K in MDCK (abst) 1317
tubuloglomerular feedback in JG of Amphiuma .. . 32:S-69
tubulointerstitial hypertrophy, hyperplasia 401
Epitheliod cells
hypotonic stress-induced release of KHCO3 891
Epithelium
adhesion, anti-DNA antibodies (abst) 1054
chloride concentration in MD and CTAL 32:S-52
differential gene expression in ischemia recovery. . . . 1157
glomerular visceral, antigen processing 71
homeobox genes in PT 1027
osmotic water flow in PT 672
tubulocystic 450
Erythrocyte complement receptor
monkey model of IC-mediated GN 44
Erythrocytosis, transplant, captopril (abst) 1321
Erythropoietin
anemia (abst) 1306
dialysis (abst) 202, 1319
dosage (abst) 203
exercise and HD (abst) 1309
ferrokinetics, 02 (abst) 202
hemodynamics (abst) 1324
hemorrhage, transfusion (abst) 1306
oxygen capacity (abst) 1306
polyamines in anemia of ESRD 725
therapy (abst) 1331
Erythrocytosis, HD (abst) 1329
Essential hypertension
glomerular hypertension 966
malignant hypertension (abst) 357, 358
1372 Subject Index: Vol. 39
Excretion
beta blockade, albumin (abst) 1307
defective oxalate transport, nephrolithiasis 1284
diuretics 336
endothelin effects on TGF 32:S-l23
hematuria in children 707
luminal Ang II in PT Na 32:S-34
modulation of K by anions 1207
potassium transtubular gradient (abst) 1334
reduced renal mass, TGF 32:S-103
role of K in hypertension 771
urinary Ca, K 973
Exercise
hemodialysis (abst) 355
oxygen capacity and EPO (abst) 1306
Extracellular matrix, fibrosis 550
Fatty acids
arachidonic acid metabolism 438
dietary prostaglandin precursors, progression 31:S-57
in focal glomerulosclerosis 930
obese Zucker rats 1126
profiles in CRF (abst) 356
Fe receptors, regulation for IgG 87
Femoral fracture, Beta2-rnicroglobulin in bone 990
Fibrinolysis, angioplasty, central vein obstruction 761
Fibrins
procoagulant activity in GN 1214
serum urokinase (abst) 1061
Fibroblasts
biochemistry (abst) 1312
cortical and papillary differentiation (abst) 1311
Fibronectin, origin (abst) 1304
Fibrosis
cyclosporine 631
mechanisms of tubulointerstitial 550
Filtration fraction
albumin excretion (abst) 1053
reduced renal mass, TGF 32:S-103
Fistulas
central vein obstruction, angioplasty and fibrinolysis. . 761
measurement of A-V (abst) 196
Fluorescence




Free amino acid content in HD 984
Free radicals, puromycin nephrosis 920
Furosemide




Galactosemia, glomerular permeability barrier 1104
Gamma-interferon
induce MHC-class 11 antigens (abst) 1302
Gamma-malanocyte stimulating hormone 63
Gancyclovir, cytomegalovirus (abst) 1319
Genes
c-myc induces PKD 665
differential expression, ischemic recovery 1157
frequency of DQw7 allele in IgAN 961
marker SGP-2 for hydronephrosis 1098
markers for ADPKD (abst) 1307
renin expression, polymerase chain reaction 32:S-23
Genitourinary tuberculosis (abst) 209
Gentamicin
lysosomal enzymes of PT 639
nephrotoxicity 639
Glomerular basement membrane
anionic sites, PAN (abst) 206
anti-entactin antibodies in GN 996
collagen (abst) 1302
development of kidney 382
nephritogenic tubulointerstitial antigens 501
sodium handling, deep nephrons, GN 850
ultrastructure seen by deep etch, quick freeze 659
Glomerular filtration rate
afferent arteriole, MD generated signals 32:S-75
beta2-microglobulin kinetics in ESRD 909
blood flow dynamics in autoregulation 32:S-99
endothelin effects on TGF 32:S-123
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